We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes

Expanded access is currently available for this treatment.
Verified September 2017 by Eli Lilly and Company
Sponsor:
ClinicalTrials.gov Identifier:
NCT01724580
First Posted: November 12, 2012
Last Update Posted: September 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Eli Lilly and Company
November 5, 2012
November 12, 2012
September 22, 2017
 
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
The Requesting Physician/Investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Not Provided
Expanded Access
Drug: Baricitinib
Administered orally
Other Names:
  • LY3009104
  • INCB 028050
Not Provided
 
Available
Contact: There may be multiple sites in this expanded access program. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559
United States
United Kingdom
 
NCT01724580
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
September 2017